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Dendrimer functionalized folate-targeted gold nanoparticles for 
luciferase gene silencing in vitro: A proof of principle study
Use of exogenous small interfering RNA (siRNA) has 
shown potential in gene silencing. The need for target-spe-
cific siRNA delivery vehicles is crucial to successful gene 
silencing. This study is aimed at developing and evaluating 
the safety and efficiency of siRNA delivery using unmodi-
fied and folic acid (FA) modified poly(amidoamine) genera-
tion 5 (PAMAM G5D) functionalized gold nanoparticles 
(Au:G5D/Au:G5D:FA) in vitro. All formulations were physico- 
-chemically characterized and nanocomplexes were evalu-
ated using the band shift, dye displacement, nuclease pro-
tection, MTT cell viability, and luciferase reporter gene 
assays. Nanocomplexes bound and protected siRNA 
against degrading RNases, and were well tolerated by the 
cells. The Au:G5D:FA nanocomplexes elicited excellent 
gene silencing in folate receptor expressing HeLa-Tat-Luc 
cells, decreasing significantly in the presence of excess FA 
ligand, indicating nanocomplex uptake by the mechanism 
of receptor mediation. These results highlight the synergistic 
role played by Au and the dendrimer in enhancement of 
transgene silencing.
Keywords: siRNA, gold nanoparticles, dendrimers, folic 
acid, gene silencing
Small interfering RNA (siRNA) has evoked much interest as an effective gene knock-
down tool in gene therapy, with potential in treating various incurable disorders such as 
cancer and acquired immunodeficiency syndrome (AIDS) (1). This gene knockdown ability 
of siRNA can be accredited to the endogenous elegant RNAi mechanism, discovered by 
Fire and Mello in the late 1990s, which regulates gene expression by silencing disease in-
ducing genes. Upon delivery of the long, double-stranded RNA (dsRNA) into the cyto-
plasm of eukaryotic cells, it is subjected to cleavage by the Dicer enzyme into short 21–25 
base pair (bp) fragments known as siRNAs. These siRNAs are then loaded into an RNA-
induced silencing complex (RISC), triggering RISC activation by the guide strand (anti-
sense) of the siRNA duplex. The activated RISC then cleaves the complementary strand of 
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the target mRNA, resulting in its degradation by intracellular nucleases, and silencing of 
gene expression (2–3).
Introduction of synthetic siRNA in various mammalian cancer cell lines has been 
reported to induce the same effect as the inherently produced dsRNA, but the long term 
gene silencing attained through repeated systemic administrations has raised questions 
on its potential as a key therapeutic agent. The inability to bypass the cellular membrane 
due to their hydrophilic and polyanionic nature, and rapid enzymatic degradation, due to 
the presence of a hydroxyl group at the second carbon atom of the sugar moiety that favors 
hydrolysis of the phosphodiester backbone, leads to poor gene silencing, which has limited 
its application to date (4–5). Hence, designing appropriate carriers that are safe and will 
protect the siRNA from the degrading enzymes while facilitating its targeted uptake by 
specific cells is a major hurdle in its therapeutic application.
Cationic polymers, such as dendrimers, have been explored as effective pDNA vectors 
due to their associated high transfection efficiency. The relatively high cytotoxicity of cat-
ionic dendrimers, PAMAM in particular, due to nonspecific interactions of primary amine 
groups with the cell membrane, is the main concern for their potential application in gene 
therapy studies. In the present study, two approaches have been used to reduce the cyto-
toxicity of PAMAM dendrimers while preserving their gene delivery efficiency. First, ter-
minal amines of the dendrimer were also modified with gold nanoparticles, forming less 
toxic NPs. Second, terminal amines of the dendrimers were also partially tailored with a 
targeting ligand, folic acid, producing folate targeted dendrimer grafted gold nanoparti-
cles (FA:G5D:AuNPs) with reduced toxicity. This study was focused on designing, charac-
terizing and evaluating the cytotoxicity profiles of untargeted and FA targeted PAMAM 
grafted AuNPs in various mammalian cell lines and their ability to efficiently deliver 
siRNA to HeLa-Tat-Luc cells to elicit the required gene silencing.
EXPERIMENTAL
Materials
Starburst poly(amidoamine), PAMAM dendrimer, generation five (PAMAM G5D), 
bicinchoninic acid (BCA), folic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
(EDC), dimethylformamide (DMF), sodium dodecylsulphate (SDS), ribonuclease A (RNase 
A) and dialysis tubing (MWCO 12 000 Da) were supplied by Sigma-Aldrich (USA). DNA 
grade agarose was acquired from Bio-Rad Laboratories (USA). Tris(hydroxymethyl)-ami-
nomethane hydrochloride (Tris-HCl), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), 2-[4-(2-hydroxyethyl)-1-piperazinyl] ethane sulphonic acid (HEPES), 
 dimethyl sulphoxide (DMSO), ethidium bromide (ETB) and gold(III) chloride trihydrate 
99 % (HAuCl4) were purchased from Merck (Germany). Minimum essential medium 
(EMEM) containing Earle’s salts and L-glutamine, penicillin (500 units mL–1)/streptomycin 
(5000 µg mL–1) and trypsin-versene were purchased from Lonza-BioWhittaker (USA). Foe-
tal bovine serum (FBS) was provided by Hyclone (USA). Human cells: embryonic kidney 
(HEK293) was obtained from the American Type Culture Collection (USA), hepatocellular 
carcinoma (HepG2) and epithelial colorectal adenocarcinoma (Caco-2) cells were pur-
chased from Highveld Biologicals (Pty) Ltd. (South Africa), and HeLa-Tat-Luc was pro-
vided by the Department of Physiology (University of KwaZulu-Natal, Durban, South 
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Africa). The luciferase assay kit was purchased from the Promega Corporation (USA). The 
siGENOME non-targeting siRNA (D-001210–01) and anti-Luc siRNA (D-002050-01) 
[GAUUAUGUCCGGUUAUGUA(UU)] were obtained from Thermo Scientific Dharmacon 
Products (USA). Duplexes were prepared according to the manufacturer’s specifications in 
1 × RNA buffer to a final concentration of 20 μM and were routinely stored at –20 °C. All 
other reagents were of analytical grade and 18 MOhm water was used in reagent prepara-
tion, in addition to RNase free water for all siRNA experiments.
Synthesis of gold nanoparticles (AuNPs)
AuNPs were synthesized by HAuCl4 reduction with trisodium citrate (1 %) as previ-
ously described (6–7). The resultant colloidal solutions were stored for future use and were 
stable for 6 months.
Synthesis of PAMAM G5D modified folic acid (G5D:FA) conjugate
PAMAM G5D was modified with FA (C19H19N7O6) through a carbodiimide reaction as 
previously described (8–9) (Supplementary Fig. S1). Briefly, FA, 2.8 µmol (1.23 mg) in 3 mL 
of DMF was reacted under N2 with 38.2 µmol (7.3 mg) of EDC for 45 minutes under constant 
stirring. This was then added dropwise with stirring into the G5D solution (3 µmol, 100 µL) 
and the pH was adjusted to 9.5. This solution was stirred for 3 days under nitrogen 
and then dialyzed against 18 MOhm water for 24 hours to remove excess unreacted by-
products.
Synthesis of dendrimer grafted AuNPs (Au:G5D NPs) and folic acid targeted dendrimer 
grafted AuNPs (Au:G5D:FA NPs)
Au:G5D and Au:G5D:FA NPs syntheses were adapted from the Turkevich method to 
produce a 25:1 gold/dendrimer molar ratio (10). Unmodified G5D and synthesized G5D:FA 
conjugates were used as templates. All AuNPs were dialyzed as previously described to 
remove unreacted by-products.
Nanocomplex preparation
Increasing amounts of NPs ranging from 2–8 mg were mixed with either 0.5 µg siCON-
TROL Tox siRNA for binding studies or 0.27 µg anti-Luc siRNA for cytotoxicity and trans-
fection studies in 32 µL sterile Hepes buffered saline (HBS). This was followed by brief 
mixing and centrifugation at 13000 revolutions/minute (rpm) for 5 minutes, and a 60 min-
ute incubation at room temperature.
Transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA)
A Jeol JEM-1010 transmission electron microscope fitted with a MegaView III digital 
camera and iTEM UIP software (Japan), set at an acceleration voltage of 200 kV, was used 
to view the morphology of the synthesized nanoparticles and their nanocomplexes pre-
pared at endpoint ratios. NTA (NanoSight NS500; Malvern Instruments Ltd., UK) was 
used to determine the hydrodynamic diameters and zeta potentials of the nanoparticles 
and their nanocomplexes at optimum binding ratios.
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Ultra-violet (UV) and proton nuclear magnetic resonance (1H NMR) spectroscopy
Attachment of G5D and FA onto the AuNP surface was confirmed using UV-Vis spec-
troscopy (UV-1650PC, Shimadzu, Japan) and 1H NMR spectroscopy (Bruker DRX 400), 
using deuterated (D2O) water as a solvent.
Gel retardation assay
Nanocomplexes at varying (m/m) ratios, containing gel loading buffer (50 % glycerol, 
0.05 % bromophenol blue, 0.05 % xylene cyanol), were subjected to electrophoresis on a 2 
% (m/V) agarose gel containing ETB (1 µg mL–1), in 1 X electrophoresis buffer [36 mmol L–1 
Tris-HCl, 30 mmol L–1 sodium phosphate (NaH2PO4), 10 mmol L
–1 ethylenediamine tetra-
acetic acid (EDTA), pH 7.5], for 1 hour at 50 V. The gels were viewed and images were 
captured at exposure times of 1–2 seconds using a Vacutec Syngene G: Box BioImaging 
system (Syngene, UK).
Ethidium bromide intercalation assay
Compact binding of siRNA to the NPs was assessed fluorescently using a Glomax®-
Multi+ detection system (Promega), set at an excitation wavelength of 520 nm and an emis-
sion wavelength of 600 nm (11). ETB (24 µL, 100 µg mL–1) was mixed with HBS (100 µL) in 
a 96-well FluorTrac flat bottom black plate and relative fluorescence (RF) was used as base-
line (0 %) fluorescence reading. The 100 % RF was set by introducing 1.3 µg siRNA to the 
mixture, which was followed by systematic addition of 1 µL aliquots of the prepared cat-
ionic NPs (0.5 µg). The RF values were recorded after each addition until a plateau in fluo-
rescence was noticed.
RNase A digestion assay
Nanocomplexes containing siRNA (0.5 µg) and varying amounts of NPs were pre-
pared at three ratios; sub-optimum, optimum, and supra-optimum as determined from 
the gel retardation assay. Nanocomplexes were exposed to 10 % RNase A for 2 hours at 37 
°C, followed by addition of EDTA and SDS to final concentrations of 10 mM and 0.5 % 
(m/V), respectively. After an additional 20 min incubation at 55 °C, the samples were sub-
jected to electrophoresis as described previously.
Cell viability: MTT assay
HEK293, HepG2, Caco-2 and HeLa-Tat-Luc cells were trypsinised and seeded into 48-
well plates at densities of 2.3–2.8 × 104 cells/well, respectively, and incubated in 0.3 mL 
complete medium [EMEM, FBS (10 %, V/V), penicillin G (100 U mL–1) and streptomycin 
sulphate (100 µg mL–1)] for 24 hours in 5 % CO2 at 37 °C. Prior to addition of the preformed 
nanocomplexes (containing 0.27 mg siRNA), the medium was replaced with fresh medium 
(0.3 mL), and cells were thereafter incubated for 48 hours at 37 °C. The medium was then 
replaced with 0.3 mL medium containing 10 % MTT reagent (5 mg mL–1 in sterile PBS), 
followed by incubation for 4 hours at 37 °C. The medium/MTT mixture was then removed, 
cells were washed twice with PBS (0.3 mL), and the resulting purple formazan salt was 
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solubilized with 0.3 mL DMSO. Absorbance values were recorded at 570 nm in a Mindray 
MR-96A microplate reader. Percentage cell viability was correlated to untreated cells (con-
trol = 100 %).
Transfection and competition assay
HeLa-Tat-Luc cells were trypsinized and seeded into 48-well plates at a density of 2.1 
× 104 cells/well and incubated in 0.3 mL complete medium for 24 hours at 37 °C. Thereafter, 
the prepared nanocomplexes (containing 0.27 mg siRNA) were added as previously de-
scribed and the cells were incubated for an additional 48 hours at 37 °C. Cells were then 
washed with PBS (2 × 0.5 mL) and lysed with 80 µL/well cell lysis buffer for 15 min on a 
Scientific STR 6 platform rocker at 30 rpm. Cell lysates were obtained by centrifugation at 
12,000×g for 1 min. To 20 µL of each cell-free extract (supernatant), 100 µL of  luciferase 
assay reagent was added, mixed and luminescence was measured in relative light units 
(RLU) on a Glomax®-Multi+Detection System (Promega Biosystem, USA). Protein concen-
trations of cell-free extracts were determined using the standard BCA assay, and the lucife-
rase activity was expressed as RLU/mg protein.
For competition studies, 50 mM of folic acid solution was incubated with the cells for 
20 min at 37 °C prior to the addition of nanocomplexes. Thereafter, the luciferase activity 
and protein concentration were determined as above.
Statistical analysis
Cell viability and transfection studies were performed in triplicate and the results 
were expressed as means ± standard deviation (SD). Experimental data was analyzed by 
two-way ANOVA and t-test, using GraphPad Prism 6.0 and statistical significant values 
are indicated by * p < 0.05, # p > 0.05, ** p < 0.01, and *** p < 0.001.
RESULTS AND DISCUSSION
Morphology, size and zeta potential of nanoparticles and nanocomplexes
Dendrimer functionalization of AuNPs is a promising advancement in the design of 
efficient non-viral delivery vectors (12). Conjugation of G5D onto AuNPs, as well as attach-
ment of FA moieties onto G5D, were verified using UV (Fig. S2, Supplementary) and 1H 
NMR spectroscopy (Fig. S3-4, Supplementary). The surface plasmon resonance (SPR) peak 
at 536 nm indicated the formation of AuNPs, with the shift to a longer wavelength of 566 
nm suggesting a modification of the AuNP surface due to the attachment of G5D. The ab-
sorption peak at 287 nm for Au:G5D:FA correlates with that of FA, suggesting successful 
attachment of the FA moiety (13–14). In 1H NMR spectroscopy, which was confirmed from 
literature, the chemical shift between 2.25–3.34 ppm, representing the amino (NH2) and 
methylene (CH2) proton peaks of G5D, and the characteristic proton peaks between 6.50–
8.63 ppm indicating the conjugation of FA moiety were observed (15).
TEM (Fig. 1) and NTA (Table I) revealed spherical NPs with diameters ranging from 
65–128 nm, while their nanocomplexes appeared as globular clusters with diameters rang-
ing from 124.9–162.9 nm. There were no significant differences (p < 0.05) in the mean sizes 
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Fig. 1. TEM micrographs of: a) AuNPs, b) Au:G5D, c) Au:G5D-siRNA, d) Au:G5D:FA and e) Au:G5D:FA-
siRNA. Nanocomplexes prepared at the optimum weight ratio of 5.0:1 and 8.0:1 (m/m), respectively. 
Scale bar = 100 nm.
observed when test nanocomplexes (Au:G5D and Au:G5D:FA) were compared with control 
nanocomplexes (G5D and G5D:FA). Furthermore, both the NPs and their nanocomplexes 
displayed positive zeta (ζ) potentials ranging between +29 to +87 mV and +25.2 to +40.7 mV. 
These ζ potential measurements are greater than +25 mV and are hence associated with 
relatively high colloidal stability (16). Au:G5D and Au:G5D:FA nanocomplexes exhibited 
greater stability than the G5D and G5D:FA nanocomplexes, as noted by their significantly 
higher ζ potentials. Reduced ζ potentials of the nanocomplexes may also infer little shield-
ing of positive charges of the dendrimers by the folate moieties.
                          a)
    b)                                                               c)
    d)                                                               e)
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Gel retardation assay
This assay demonstrated the ability of the prepared NPs to bind and complex the 
siRNA. This is based on the principle that was initially reported by Hellman and Fried (17) 
that during electrophoresis, nucleic acids migrate freely across the agarose gel, but when 
Table I. Mean size and ζ potential measurements of nano-scaffolds and their nanocomplexes. Data are 





Mean diameter ± SD 
(nm)
ζ Potential ± SD 
(mV)
Au – 65.90 ± 9.80 –7.3 ± 1.6
G5D – 161.3 ± 11.9 + 87.2 ± 2.4
Au:G5D – 100.5 ± 44.1 +20.9 ± 2.2
G5D:FA – 128.0 ± 1.20 +71.2 ± 3.4
Au:G5D:FA – 77.70 ± 12.5 +29.0 ± 0.5
Au:G5D-siRNA 5.0:1 124.9 ± 19.9# +38.5 ± 2.7 *
Au:G5D:FA-siRNA 8.0:1 162.9 ± 51.9# +40.7 ± 1.3 #
G5D-siRNA 5.0:1 154.9 ± 9.50# +25.8 ± 0.8 *
G5D:FA-siRNA 6.0:1 149.7 ± 5.70# +37.2 ± 1.3 #
*p < 0.05, # p > 0.05 when test nanocomplexes are compared with control nanocomplexes. NTA size and zeta potential 
distribution are reflected in supplementary notes.
Fig. 2. Gel retardation assay showing the binding of: a) G5D, b) Au:G5D, c) G5D:FA, d) Au:G5D:FA and 
siRNA. Nanocomplexes contained varying amounts of nanoparticles and 0.5 µg siCONTROL Tox 
siRNA corresponding to weight ratios of 2:1, 3:1, 4:1, 5:1, 6:1, and 7:1 in lanes 2-7, respectively (a-c); and 
3:1, 4:1, 5:1, 6:1, 7:1, and 8:1 in lanes 2-7, respectively (d). Lane 1: naked siRNA. Arrows indicate end-
point ratios.
a)                                                                       b)
c)                                                                       d)
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they are complexed with carriers, their mobility is retarded. Fig. 2 confirms that all pre-
pared NPs were capable of binding and complexing siRNA. Untargeted G5D and Au:G5D 
NPs were both completely retarded at a m/m ratio of 5:1, while the targeted G5D:FA and 
Au:G5D:FA NPs were completely retarded at m/m ratios of 6:1 and 8:1, respectively. The 
high binding ratios for G5D:FA and Au:G5D:FA NPs may be attributed to some masking of 
the cationic charges on G5D by folic acid. FA containing nanocomplexes displayed higher 
positive ζ potentials with little decrease in positive charge, as evidenced by the ζ potential 
measurements.
Ethidium bromide intercalating assay
The degree of siRNA compaction was explored by measuring the decrease in ETB 
fluorescence upon its displacement from siRNA by NP induced condensation (3, 11). In Fig. 
3, a steady decrease in fluorescence was noted upon stepwise addition of the NPs until a 
plateau was reached where no further condensation occurred. G5D and Au:G5D nanocom-
plexes attained this endpoint at 55 and 62 %, respectively, while the G5D:FA and Au:G5D:FA 
nanocomplexes reached the endpoint at 70 and 78 %, respectively. A higher degree of 
compaction is indicative of weaker binding, and suggests the possibility of easier disso-
ciation of siRNA during transfection (18).
RNase A digestion assay
Naked siRNA delivery to a target site may be compromised by degrading serum nu-
cleases. Hence, delivery vectors that will not only bind but also protect the siRNA against 
such enzymes are vital. Following exposure to 10 % RNase A, all NPs showed the ability 
to protect the siRNA across the range of tested ratios (Fig. 4). This was not the case of the 
uncomplexed/naked siRNA, as indicated by the absence of a band due to total degradation 
by RNase.
Fig. 3. Ethidium bromide displacement assay of (A) G5D, (B) Au:G5D, (C) G5D:FA, and (D) Au:G5D:FA 
nanoparticles. Arrows indicate the point of complexation.
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MTT assay
Biomedical applications of NPs as gene delivery agents often involve deliberate, direct 
injection or ingestion into the body. These NPs are often coated with bio-conjugates such 
as nucleic acids, polymers, antibodies and proteins for specific cell targeting (19). Hence, it 
is crucial to ensure that such enhancements are not detrimental to the cells. Therefore, in 
vitro toxicity evaluation of NPs is an important aspect to consider when assessing their in 
vivo potential.
The results presented in Fig. 5, show some cell specific cytotoxicity, indicated by the 
differences in the % cell numbers and the level of cytotoxicity. There was no significant 
Fig. 4. RNase A digestion of nanocomplexes: a) G5D, b) Au:G5D, c) G5D:FA, d) Au:G5D:FA. Control: 
naked siCONTROL Tox siRNA (0.5 µg) in the absence (+ means positive control) or presence (– means 
negative control) of RNase A. Lanes 1-3 NP:siRNA ratios: a) 4:1, 5:1, 6:1; b) 4:1, 5:1, 6:1; c) 5:1, 6:1, 7:1; d) 
7:1, 8:1, 9:1 (m/m). Red numbers indicate optimum binding ratios.
Fig. 5. MTT assay of the NP:siRNA nanocomplexes in HEK293, HepG2, Caco-2, and HeLa-Tat-Luc 
cells. Data are presented as means ± SD (n = 3). Control = untreated cells. *** p < 0.0001 when compared 
to the control.
                  a)                                  b)                               c)                             d)
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difference (p > 0.05) in cell viability between the tested cell lines; however, when compared 
to the control (cells only), a significant difference (p < 0.0001) in cell viability was seen. Higher 
cell viabilities observed with the Au:G5D and Au:G5D:FA nanocomplexes, ranging from 
70–90 %, suggest that they were less toxic than the G5D and G5D:FA nanocomplexes (50–70 %). 
This could be due to the presence of the biocompatible, non-immunogenic and non-cyto-
toxic AuNPs (supplementary Fig. S5), which reduced some of the amines of G5D (20–22), 
thereby reducing the cytotoxicity. Hence, lower cell viability for the G5D and G5D:FA 
nanocomplexes might be due to the increased cationic charges on the G5D even after inclu-
sion of a targeting moiety, folic acid. These findings strongly suggest that the inclusion of 
non-toxic, inert AuNPs in the formulation of these NPs had a positive and favourable influ-
ence on cellular toxicity.
Transfection and competition assay
This study evaluated the ability of the nanocomplexes to efficiently deliver siRNA to 
the folate receptor positive HeLa-Tat-Luc cells, a human cervical cell line that stably ex-
presses the firefly luciferase gene (23). The anti-Luc siRNA, which targets the firefly lucif-
erase mRNA, was used to determine the level of gene silencing.
Experimental data revealed that all nanocomplexes were internalized by the selected 
cells, either by adsorptive non-specific or specific endocytotic pathways, depending on the 
formulation (14). Lower gene silencing efficiency (34 %) was seen with naked siRNA, as 
expected, since upon delivery into the cell, naked nucleic acids such as siRNA are sub-
jected to enzymatic degradation (24). Gene silencing elicited by all nanocomplexes ranged 
from 42–70 %, with that of the Au:G5D:siRNA and Au:G5D:FA:siRNA nanocomplexes 
ranging between 50–70 %, while that for the G5D and G5D:FA nanocomplexes ranged 
between 42–51 % (Fig. 6). The weaker gene silencing observed for the G5D and G5D:FA 
nanocomplexes could be due to poor dissociation between siRNA and cationic G5D due to 
their strong binding affinity. Early studies have demonstrated a direct correlation between 
the binding affinity of nucleic acids with cationic polymers and transgene expression (25). 
These findings corroborate the studies conducted by Kang and co-workers, who associated 
unmodified and conjugated G5D with weak gene silencing efficiency (26). The highly sig-
nificant gene silencing efficiency elicited by the Au:G5D:siRNA and Au:G5D:FA nanocom-
plexes can be accredited to the presence of AuNPs entrapped in the 1o amines, which have 
been reported to help preserve the morphological aesthetics of dendrimers, permitting 
efficient interaction with siRNA (21).
These findings are in agreement with the reports by Kolhatkar and coworkers on 
surface tailored PAMAM showing good cell membrane permeability and good delivery of 
siRNA into the targeted site (27). Recent studies have also demonstrated the effectiveness 
of internally modified and surface tailored G5D in gene silencing (21, 28). The highest gene 
silencing was observed at optimum ratios for all nanocomplexes. These findings correlate 
with previous reports suggesting a possible dependency of the siRNA-dendrimer com-
plex’s gene silencing ability on the dendrimer generation, siRNA concentration and bind-
ing ratio (29).
To confirm that the uptake of the folate-targeted nanocomplexes was receptor-medi-
ated, a competition study was conducted where the FA-Rs overexpressed on the surface of 
HeLa-Tat-Luc cells were blocked with an excess of free folic acid prior to transfection with 
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the nanocomplexes. A significant (p < 0.0001) 30 % drop in gene silencing was seen (Fig. 7) 
indicating that many of these nanocomplexes were endocytosed via FA-Rs (30). Overall, 
these findings suggest that the Au:G5D and Au:G5D:FA NPs appear to be better siRNA 
delivery vehicles than G5D and G5D:FA:siRNA NPs, a finding that correlates with the cell 
viability studies.
Fig. 6. Luciferase gene silencing by anti-luc siRNA nanocomplexes. Control 1 = untreated cells. Control 
2 = cells + Anti-Luc siRNA. Data are presented as means ± SD (n = 3). #p > 0.05, ** p < 0.001 *** p < 0.0001.
Fig. 7. Receptor competition studies of FA targeted anti-luc siRNA nanocomplexes. Luciferase gene 
silencing is expressed/reported as percentage. Data are presented as means ± SD (n = 3). * p < 0.05, 
** p < 0.001, *** p < 0.0001.
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CONCLUSIONS
Both Au:G5D and Au:G5D:FA NPs were excellent siRNA delivery vehicles, forming 
stable globular nanocomplexes that displayed favourable interaction with siRNA and af-
forded good protection. Modification of surface amines of the dendrimers with the FA 
targeting ligand and the internal modification with AuNPs served to produce a reduction 
in cytotoxicity of the nanocomplexes (cell viability of up to 90 %) and increased siRNA 
induced transgene silencing (up to 75 %). In summary, we have demonstrated that Au:G5D 
and Au:G5D:FA NPs have many of the ideal characteristics required for an efficient siRNA 
delivery vehicle, and future studies are needed to evaluate these nanocomplexes in vivo.
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